Introduction {#S0001}
============

Recent advancements in biological therapies have initiated a shift from the traditional 'one-size fits all' approach towards personalized medicinal strategies. Advanced Therapy Medicinal Products (ATMPs) are at the forefront of this new tendency. ATMP is the umbrella term for three drug product classes: Somatic cell therapies, gene therapeutics and tissue engineered products as well as a combination of these technologies with a medicinal product. All ATMP classes contain either living cells or viral vectors and are therefore characterized by a high degree of complexity. Cells are usually derived from a patient or an allogeneic donor, processed in the laboratory (e.g. expanded *in vitro* or genetically engineered) and (re-) administered to the patient in a hospital. Gene therapy is designed to introduce genetic material into living cells to compensate for abnormal genes or express a beneficial protein.

On 30 December 2008, the Regulation 1394/2007 amending Directive 2001/83/EC on Advanced Therapy Medicinal Products entered into force and the first European Union wide regulatory framework for ATMPs was established \[[1](#CIT0001)\]. This framework changed the code of regulatory practices, as a central marketing authorisation issued by the European Medicinal Agency (EMA) was required from now on. Previously, registration was not required for autologous products and pivotal clinical trials were not mandatory \[[2](#CIT0002)\]. Not all ATMPs target high prevalence indications. In case of orphan diseases with a prevalence not more than 5 in 10.000, the ATMP regulation poses complex challenges to the design of clinical trials \[[2](#CIT0002),[3](#CIT0003)\].

In recognition of the small scale and developmental nature of some intra-hospital ATMP applications, the regulation 2001/83/EC includes a 'Hospital exemption' for products not intended to be marketed. ATMPs applied via Hospital exemption must be prepared on a non-routine basis in a non-industrial manner and used as a custom made product for an individual patient \[[4](#CIT0004)\]. However, the meanings of 'non-routine basis', 'industrial manner' and 'custom made' are not specified by the regulation and interpretations differ among different European countries \[[5](#CIT0005)\]. ATMPs without a centralized European marketing authorisation can therefore still be approved in individual member states.

The aim of the presented study is to give an overview on ATMPs currently available within the European Union either via a centralized marketing authorisation or via national approval in an individual member state. ATMPs withdrawn from the market will be identified and the reasons for withdrawal analysed. Additionally, a forecast on innovative ATMPs in the process of EMA approval as well as products in phase III and IV clinical trial will be presented.

Methods {#S0002}
=======

Search strategy {#S0002-S2001}
---------------

A systematic database review was conducted to identify published studies from Ovid MEDLINE, Ovid EMBASE, the Cochrane Library and clinicaltrials.gov. Details on clinical trials were also collected from clinicaltrialsregister.eu. Additional information was gathered from the homepage of the European Medicines Agency ([www.ema.europa.eu](http://www.ema.europa.eu)) as well as from the webpages of the national competent authorities. A manual search for grey literature was performed following pre-defined search terms. Additionally, the national competent authorities were contacted to obtain information on ATMPs licensed via Hospital exemption.

Key words {#S0002-S2002}
---------

ATMP, advanced therapeutic medicinal product, cell therapy, stem cell, stem cell transplantation, umbilical cord, cord blood, bone marrow, bone marrow transplantation, cancer vaccine, tissue engineering, mesenchymal stem cell, somatic cell, allogeneic cell, viable cell, tissue engineering, gene therapy, recombinant nucleic acid, recombinant DNA, nucleic acid therapy, gene transfer, virus delivery, cancer immunotherapy, RNA therapy, tumor vaccine, plasmid DNA, oligonucleotide, transgenic microorganism, genetically modified microorganism, transformed cell line, genetically modified cell line, gene vector, vector

Eligibility criteria {#S0002-S2003}
--------------------

Publications targeting an ATMP approved by the EMA or in the process of an EMA approval as well as manuscripts targeting phase III and IV ATMP clinical trials were included in this review. Additionally, publications on ATMPs administered to patients via Hospital exemption were included. Products were excluded from evaluation if their ATMP status could not be clearly assessed, e.g. in case of cancer immunotherapeutics which had neither been submitted to the EMAs Committee for Advanced Therapies (CAT) for classification nor declared as ATMP in the reference literature. Further inclusion and exclusion criteria are detailed in [Table 1](#T0001).10.1080/20016689.2019.1600939-T0001Table 1.Inclusion and exclusion criteria.Inclusion criteriaExclusion criteriaApplication human medicinePublications on basic research or animal experiments without direct clinical applicationInterventional product classified as ATMPArticles targeting rules and regulations were used as background information onlyInterventional product is either a licensed ATMP, an ATMP with a marketing license application or applied via hospital exemption or in phase III or IV clinical trialArticles on phase I and II clinical trials if no subsequent phase III trial was reportedIntervention taken place within an EU member stateOther than European countriesLanguage of publication German or EnglishArticles in languages other than English or German Articles not publicly available

Data extraction {#S0002-S2004}
---------------

The following clinical trial data were extracted using MS Excel 2011: ATMP, registration number, manufacturer, indication, clinical trial status and eventual marketing authorisation status. Duplicates with the same registration number were removed as well as all pre-clinical, phase I and II studies, observational studies, studies performed outside the European Union and studies with an unclear phase assignment. Clinical trials not targeting an ATMP as well as generic conference abstracts not containing concrete clinical data were also excluded.

Results {#S0003}
=======

Search results {#S0003-S2001}
--------------

The literature search yielded 2.613 publications. After removal of duplicates, pre-clinical, phase I and II studies, observational studies and studies with an unclear phase assignment 502 full text records were considered for evaluation. 91 did not meet the inclusion criteria (mostly studies performed outside of the European Union). Finally, we identified 412 studies for investigation.

The clinical trials database search yielded 1.946 entries in European Union member states. In 1.516 trials, the interventional drug was not an ATMP. 430 clinical trials were included in the evaluation. After manual removal of duplicates resulting from multi-centre international clinical trials, 160 phase III and IV studies were reviewed. 20 did not meet the inclusion criteria (either erroneously reported as phase III in the database or not targeting an ATMP). Finally, 141 clinical trials were included in the evaluation. A flow chart of clinical trial identification and inclusion is presented in [Figure 1](#F0001).10.1080/20016689.2019.1600939-F0001Figure 1.Flow chart of clinical trial identification and inclusion.

ATMPs with a valid central European marketing authorisation {#S0003-S2002}
-----------------------------------------------------------

Since approval of the first ATMP in 2009, 12 products have obtained a central European marketing authorisation by the European Medicines Agency. An overview on these products is presented in [Table 2](#T0002). By the end of August 2018, 4 licensed ATMPs had retired from the market. Currently 8 ATMPS are available within the European Union: The gene therapies **Imlygic®, Strimvelis**®, and **Zalmoxis**® and the cell based therapies **Holoclar®, Spherox**® and **Alofisel**®. In August 2018, the European Medicines Agency recommended the first two marketing authorisations for chimeric antigen receptor (CAR) T-cells medicines, **Kymriah**® (tisagenlecleucel) and **Yescarta**® (axicabtagene ciloleucel). Both substances belong to a new generation of individualized cancer immunotherapies based on the modification of the patients' immune cells for cancer treatment \[[6](#CIT0006)\]. Details on ATMPs with a valid central European marketing authorisation are summarized in [Table 3](#T0003).10.1080/20016689.2019.1600939-T0002Table 2.Overview on ATMPs with past/present marketing authorisation.NameAuthorisation holderIndicationAuthorisation numberApproval dateStatus**Yescarta®**Kite PharmaB-cell lymphomaEMEA/H/C/00448008/2018APPROVED**Kymriah®**NovartisALL, DLBCLEMEA/H/C/00409008/2018APPROVED**Alofisel®**TiGenixPerianal fistulas in Crohn´s diseaseEMEA/H/C/00425803/2018APPROVED**Spherox®**CO.DONCartilage defects in the knee jointEU/1/17/118105/2017APPROVED**Zalmoxis®**MolMedStem cell transplantation in high-risk blood cancerEMEA/H/C/00280106/2016APPROVED**Strimvelis®**GSKADA-SCIDEU/1/16/109704/2015APPROVED**Imlygic®**AmgenMelanomaEU/1/15/106409/2015APPROVED**Holoclar®**ChiesiSevere limbal stem cell deficiency in the eyeEU/1/14/98703/2015APPROVED**Provenge®**DendreonMetastatic prostate cancerEMEA/H/C/00251310/2013withdrawn in 2015**MACI**VericelCartilage defects in the knee jointEU/1/13/84707/2013withdrawn in 2014**Glybera®**UniqureLipoprotein Lipase DeficiencyEU/1/12/791/00111/2012withdrawn in 2017**Chondro**\
**Celect®**TiGenixCartilage defectsEMEA/H/C/00087811/2009withdrawn in 2016[^1]10.1080/20016689.2019.1600939-T0003Table 3.ATMPs with a valid central European marketing authorisation by August 2018.**Holoclar®**Holoclar**®** was the first stem cell based ATMP approved by the European Union. The product is based on *ex vivo* expanded autologous human corneal epithelial cells \[[10](#CIT0010)\]. The cells are isolated from a limbus tissue biopsy, expanded *in vitro* and cryopreserved for alignment with the patient´s medical care. After thawing, the cells are seeded onto a fibrin matrix for transplantation \[[11](#CIT0011)\].**Imlygic®**Imlygic**®**was the first oncologic gene therapy reaching EMA approval. The product is based on a genetically modified oncolytic virus replicating within the tumoral tissue to produce granulocyte-macrophage colony stimulating factor (GM-CSF). Intratumoral application leads to tumor cell lysis and the release of tumor-derived antigens, which -- in combination with GM-CFS -- amplify the body´s anti-tumoral immune response \[[12](#CIT0012)\].**Strimvelis®**Strimvelis**®** is designed to treat severe combined immunodeficiency (SCID) due to Adenosin desaminase deficiency (ADA-SCID) in patients who cannot be treated with a bone marrow transplant due to lack of a suitable donor \[[13](#CIT0013)\]. The product is based on autologous CD 34+ cells transduced with a retroviral vector encoding for the human ADA cDNA sequence \[[10](#CIT0010)\].**Zalmoxis®**Zalmoxis**®** is a patient specific immunogenic therapy serving as adjunctive treatment in haplo-identical haematopoietic stem cell transplantation in patients with leukaemia and high-risk haematological malignancies \[[14](#CIT0014)\]. Data from 45 patients treated with Zalmoxis showed a survival rate of 49% after one year. Survival in the control group was 37% \[[15](#CIT0015)\].**Spherox®**Spherox**®** are spheroids of human autologous matrix-associated chondrocytes for treatment of cartilage defects in the knee joint \[[16](#CIT0016)\]. Data of 30 patients after an average follow-up of 3 years demonstrate a significant increase in quality of life, pain reduction and an improvement of joint function \[[17](#CIT0017)\].**Alofisel®**Alofisel**®** consists of adipose tissue derived allogeneic mesenchymal stem cells for injection into the perianal fistula tract in Cohn's disease \[[18](#CIT0018)\]. Local application of Alofisel**®** in conjunction with surgical preparation of the fistula tract has been shown to induce and maintain fistula closure, but a high placebo effect due to background therapies was noted in the phase III clinical trial \[[19](#CIT0019)\].**Kymriah®**Kymriah**®** (**CTL019/tisagenlecleucel**) is intended for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia and for adult patients with diffuse large B-cell lymphoma who are ineligible for stem cell transplantation. In paediatric patients, an overall remission rate of 81% was achieved in the ELIANA trial \[[20](#CIT0020)\]. Adult patients with diffuse large B-cell lymphoma achieved an overall response rate of 52% \[[21](#CIT0021)\]. Treatment related adverse events occurred in 95% of the patients, mostly as cytokine release syndrome.**Yescarta®**Yescarta**®** (**axicabtagene ciloleucel**) is a chimeric antigen receptor T-cell therapy to treat aggressive non-Hodgkin´s lymphomas. In patients with large B-cell lymphoma, primary mediastinal B-cell lymphoma and transformed follicular lymphoma, the overall response rate was 71%. Complete remission was achieved in 57% (5/7) of the patients \[[22](#CIT0022)\]. Adverse events include anaemia, neutropenia and decreased white blood cell count. Grade III or higher cytokine release syndrome is observed in 13% and neurologic events in 28% of the patients \[[23](#CIT0023)\]. 71% of the patients treated for relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL) responded to the treatment either as complete response or complete response with incomplete hematologic recovery \[[24](#CIT0024)\]. However, one patient experienced a fatal cytokine release syndrome \[[25](#CIT0025)\].

ATMPs withdrawn from the market {#S0003-S2003}
-------------------------------

Provenge®, MACI, Glybera® and ChondroCelect® have been withdrawn from the market. **Provenge**® (Sipuleucel-T) was a cellular immunotherapy for treatment of metastatic castration resistant prostate cancer. The substance was able to prolong median patient survival by 4,1 months. After a 3 years follow up, the proportion of patients alive in the vaccine group was 50% higher than in the control group \[[7](#CIT0007)\]. Provenge® was approved by the EMA in 2012 and priced \$93.000 per treatment \[[8](#CIT0008)\]. Supply chain conditions were highly complex: Within a cooled, insulated container, shelf live was only 18 hours \[[9](#CIT0009)\]. Due to the high price, a highly complex way of administration and reimbursement issues the product failed on the market and the manufacturer filed bankruptcy in 2015 \[[8](#CIT0008)\].

**MACI** was on the market since 1998 in individual EU countries according to national procedures \[[10](#CIT0010)\]. In 2013, the product was granted a central marketing authorisation for repair of cartilage defects in the knee joint. Due to commercial reasons, the company closed the European manufacturing site in 2014. Consequently, the marketing authorisation was suspended and expired during the suspension period \[[11](#CIT0011)\].

**Glybera**® was an adenoassociated viral vector for treatment of lipoprotein lipase deficiency (LLD), a ultra-rare disease affecting only 1 in a million people \[[12](#CIT0012)\]. The product was authorised under exceptional circumstances based on data received from 3 phase III trials enrolling a total of 27 patients \[[13](#CIT0013)\]. Despite the clinical success, the product was a commercial failure. Four and a half years after making history for obtaining EMA approval as the first gene therapy in a regulated market, the manufacturer did not renew marketing approval and Glybera® was withdrawn in October 2017. In fact, only one patient had been treated with the commercial form of the LLD therapy, which was priced at 1,1 Million € \[[14](#CIT0014)\].

**ChondroCelect**® (characterized, viable autologous cartilage cells expanded *ex vivo* expressing specific marker proteins) was approved in October 2009. The pivotal clinical trial demonstrated a superior structural cartilage repair when compared to standard Microfracture treatment \[[15](#CIT0015)\]. Despite positive results, the product was withdrawn from the market in 2016 due to a lack of reimbursement in key European countries \[[9](#CIT0009)\].

ATMPs in the process of EMA approval (planned launch before 2020) {#S0003-S2004}
-----------------------------------------------------------------

Until 2020, 6 new ATMPs shall be launched on the European market. Developing companies, indications and clinical/regulatory status are summarized in [Table 4](#T0004). The Committee for Medicinal products for Human Use (CHMP) has already recommended the granting of a marketing authorisation for **Luxturna**™, a gene therapy for treatment of inherited retinal dystrophy \[[16](#CIT0016)\]. **LentiGlobin**™ is a potential gene therapy for correction of transfusion dependant thalassemia and sickle cell disease. Published data from the phase I/II study report that 4 out of 7 patients remained transfusion free for more than 90 days \[[17](#CIT0017)\]. **Lenti-D**™ is another gene therapy for treatment of childhood cerebral adrenoleukodystrophy, a genetic disease causing progressive damage to the brain \[[18](#CIT0018)\]. The cell therapeutic product **Habeo**™ is an injection of adipose-derived regenerative cells to treat hand involvement in systemic sclerosis \[[19](#CIT0019)\]. Despite not reaching significance in the phase III trial, clinically meaningful improvements in hand function were achieved in a subgroup of patients with diffuse cutaneous scleroderma \[[20](#CIT0020)\]. A managed access programme is currently being established to provide access for patients in advance of the full marketing authorisation \[[21](#CIT0021)\]. **Neocart**® is an autologous chondrocyte-based tissue implant. In contrast to the promising phase I and II results, the primary efficacy endpoints were not met in the subsequent phase III clinical trials \[[22](#CIT0022)\]. As the data are still being analysed, eventual consequences for the European market launch are currently unclear. **ATIR101** is a cell based immunotherapeutic product containing T-lymphocyte enriched leukocytes. The product is intended to restore lymphocyte levels in patients undergoing stem cell transplantation from a partially matched (haploidentical) family donor. Conditional approval is expected for Q1 2019.10.1080/20016689.2019.1600939-T0004Table 4.ATMPs in the process of marketing authorisation or with a planned marketing launch.ProductDeveloperIndicationRegulatory/\
Clinical status**Luxturna^TM^**NovartisBiallelic RPE65-mediated retinal dystrophyMAA submitted\
EMA: CHMP pos. opinion 09/2018\
Phase III\
NCT00999609\
Open-label, randomized controlled trial\
At least 24 patients planned\
Estimated study completion date 2029**LentiGlobin^TM^**BlueBird BioTransfusion dependant ß-thalassemia, sickle cell diseaseMAA submitted\
EMA: accelerated approval granted\
Phase III\
NCT02906202\
Single arm, multi site, single dose study\
Approx. 23 patients planned\
Estimated study completion date 2020**Habeo^TM^**Cytori TherapeuticsHand dysfunction due to sclerodermaEMA: Orphan drug designation granted\
Phase n.a.\
NCT02396238\
prospective, randomized, multi-center device trial\
88 patients enrolled\
Study completion date 2018**Lenti-D^TM^**BlueBird BioCerebral adrenoleukodystrophyPhase II/III\
NCT01896102\
Single arm open label\
30 patients planned\
Estimated study completion date 2021**Neocart®**Histogenics corporationCartilage repairPhase III\
NCT01066702\
245 participants enrolled\
Randomized, open label\
Estimated study completion date 2020**ATIR101**Kiadis PharmaAML, ALL or myelodysplastic syndromeMAA submitted\
response to EMA submitted 03/2018\
Phase III\
NCT02999854\
Randomized controlled multicenter open-label study\
250 participants planned\
Estimated study completion date 2021**JCAR 017**CelgeneDLBCLEMA: PRIME\
Phase III\
NCT03575351\
Randomized open label study\
182 participants planned\
Estimated study completion date 2023**bb2121**CelgeneMultiple myelomaEMA: PRIME eligibility 11/2017\
Phase III\
NCT03651128\
Multicenter randomized open label\
381 participants planned\
Estimated study completion date 2025**Tab-cel^TM^**Atara BiotherapeuticsEBV associated post-transplant lymphoproliferative disorderPhase III\
NCT03392142\
Multi-center, single arm, open label\
33 participants planned\
Estimated study completion date 2020**Lenadogene nolparvovec**GenSight Biologics SAVision loss from Leber hereditary optic neuropathyPhase III\
NCT02652767\
Randomized, double-masked, sham-controlled clinical trial\
36 participants planned\
Estimated study completion date 2019**REX-001**RexgeneroCritical limb ischemiaEMA: Certificate for manufacturing and non-clinical data 01/2018\
Phase III\
NCT03174522\
Randomized, double-blind, controlled clinical trial\
78 participants planned\
Estimated study completion date 2021**Multistem**AthersysIschemic strokePhase III\
NCT03545607\
Randomized, quadruple-masked clinical trial\
300 participants planned\
Estimated study completion date 2021**PLX-PAD**Pluristem therapeuticsCritical limb ischemiaPhase III\
NCT03006770\
Multicenter randomized controlled clinical trials\
246 participants planned\
Estimated study completion date 2020[^2]

ATMPs with a planned launch in or after 2020 {#S0003-S2005}
--------------------------------------------

Two further CAR T-cell therapies currently in phase III clinical trial are planned for a centralized European market approval: **JCAR017** (lisocabtagene maraleucel, liso-cel) is a treatment for aggressive B-cell non-Hodgkin´s lymphoma. Data from the phase I study demonstrated an overall response rate of 66% with 50% of the patients achieving complete response at three months \[[23](#CIT0023)\]. **bb2121** is intended to treat multiple myeloma. Published efficacy data from the phase I trial report an overall treatment response of 95,5% \[[24](#CIT0024)\]. Filing of a marketing authorisation application is anticipated for 2019 \[[25](#CIT0025)\].

**Tab-cel^TM^** is an allogeneic T-cell immunotherapy to treat Epstein Barr Virus (EBV) associated post-transplant lymphoproliferative disorder and other EBV associated tumors \[[26](#CIT0026)\]. The product was accepted into the EMA Priority Medicines regulatory pathway and is available to eligible patients through a multicentre expanded access protocol \[[27](#CIT0027)\]. Evaluation of the expanded access programme demonstrates a response rate of 80% after hematopoietic stem cell transplantation and 83% after solid organ transplantation at a medium follow up of 3,3, months. Overall survival at 1 year among all patients treated was 90,3% \[[28](#CIT0028)\].

**Lenadogene nolparvovec** (GS-010) is a gene therapy for treatment of Leber's hereditary optic neuropathy (LHON), a genetic disorder leading to a rapid loss of bilateral central vision \[[29](#CIT0029)\]. **REX-001 (Rexmylocel)** are autologous bone marrow mononuclear cells administered through an intra-arterial catheter to treat critical limb ischemia \[[30](#CIT0030),[31](#CIT0031)\]. **Multistem®** is an off the shelf cell therapy product applicable for treatment of multiple distinct diseases. Multistem cells are currently in phase III clinical trials for treatment of ischaemic stroke and phase II for ulcerative colitis \[[32](#CIT0032),[33](#CIT0033)\]. Phase I studies for acute myocardial infarction and Graft vs. Host Disease have been completed \[[34](#CIT0034),[35](#CIT0035)\].

**PLX-PAD PL**acental e**X**panded cells are mesenchymal-like stromal cells applicable without tissue or genetic matching. The cell-released cytokines, chemokines and growth factors are supposed to facilitate tissue regeneration \[[36](#CIT0036)\]. PLX-PAD was granted FDA fast track approval and was accepted into the EMA Adaptive Regulatory Pathway \[[36](#CIT0036)\] . Data of all ATMPs with a planned launch in or after 2020 are summarized in [Table 4](#T0004).

ATMPS available in individual European member states via hospital exemption {#S0003-S2006}
---------------------------------------------------------------------------

A survey performed by the Pharmaceutical Committee of the European Commission in 2012 reported that 37% of the responding European member states had ATMPs legally on the market and 22% had issued Hospital exemptions for ATMP products \[[37](#CIT0037)\]. In 2018, 47% of the responding countries reported to have issued Hospital exemptions. Data are summarized in [Table 5](#T0005).10.1080/20016689.2019.1600939-T0005Table 5.Hospital exemption for ATMPs.CountryHospital exemption issued in 2012Hospital exemption issued in 2018Cell types applied via Hospital exemption**Austria**nono **Belgium**yesno **Bulgaria**?? **Croatia**no? **Cyprus**no? **Czech Republic**noyesChondrocytes**Denmark**yes? **Estonia**nono **Finland**no? **France**yes? **Germany**yesyesCytokine induced killer cells, dendritic cells, chondrocytes, mesenchymal stroma cells, engineered oral mucosa, bone marrow derived progenitor cells**Greece**no? **Hungary**nono **Iceland**nono **Ireland**noyesLimbal stem cells**Italy**no? **Latvia**nono **Liechtenstein**?? **Lithuania**noyesDendritic cells, cytokine activated killer cells,T-cells, stromal vascular fraction cells**Luxembourg**no? **Malta**no? **Netherlands**yesyesLymphocytes, mesenchymal stem cells, mononuclear cells, T-cells**Norway**?yesChondrocytes, autologous T-cells, autologous dendritic cells, skin cells**Poland**no? **Portugal**nono **Romania**no? **Slovakia**no? **Slovenia**no? **Spain**yes? **Sweden**noyesChondrocytes, mesenchymal stem cells, mesenchymal stromal cells, fetal stem cells, keratinocytes**UK**nono 

The national competent authorities of Germany, Czech Republic, Ireland, Lithuania, Norway, Sweden, Italy and the Netherlands stated to have national approvals for ATMPs. No national approvals are currently issued in Austria, Belgium, Estonia, Hungary, Iceland, Latvia, Portugal and the UK. Tumor vaccines and autologous chondrocytes for restoration of cartilage defects are the most commonly used ATMP products under the Hospital exemption. Other cell types applied are oral mucosa cells, skin cells, bone marrow derived and mesenchymal stem cells as well as limbal stem cells ([Figure 2](#F0002)).10.1080/20016689.2019.1600939-F0002Figure 2.ATMP products applied in individual European member states via Hospital exemption.

ATMPS in phase III or IV clinical trial {#S0003-S2007}
---------------------------------------

Apart from ATMPs following the centralized marketing authorisation pathway, 141 phase III and four phase IV clinical trials investigating potential ATMPs were identified. The majority (74%) of these are academic trials without an industrial sponsor. The remaining 26% are industry-driven research projects examining 31 different ATMP candidates. Indications are coronary artery disease, urinary stress incontinence, critical limb ischemia and chronic leg ulcers as well as cartilage restoration, oncological indications, mucopolysaccharidosis and spinal muscular atrophy. Most ATMP candidates in the industrial pipeline are cancer vaccines (29%), followed by gene (25%) and stem cell therapies (23%). Details are presented in [Figure 3](#F0003). 13 studies are still active at the time of this report and have no results published. 3 studies with published results failed to demonstrate clinical efficacy in phase III. The marketing authorisation application of Cerepro® (Ark Therapeutics) was withdrawn for this reason \[[38](#CIT0038)\]. Data on potential ATMPs in the industrial pipeline are summarized in [Table 6](#T0006).10.1080/20016689.2019.1600939-T0006Table 6.ATMP candidates in the industrial pipeline in phase III/IV clinical trial.ATMP candidateClinical trial identifierSponsorIndicationStudy StateAutologous CD133+ bone marrow stem cellsNCT00950274Miltenyi Biotec GmbHChronic ischemic coronary artery diseaseTerminated (slow recruitment)Skeletal muscle derived cells2014--001656-34Innovacell Biotechnologie AGStress urinary incontinenceCompletedTumor site allografts of healthy endothelial cells embedded in polymer matrixUnknownShire (Pervasis)Treatment/\
Prevention of metastatic cancerUnknownBone marrow derived mononuclear cellsNCT01285297CardiogenesisTransmyocardial revascularisationCompletedC-CURE (bone marrow derived cardiopoietic cells)NCT01768702Celyad (formerly named Cardio3 BioSciences)Ischaemic heart failureCompletedGenerx (FGF-4 gene therapy)NCT02928094Angionetics Inc.Coronary artery diseaseCompletedRiferminogene pecaplasmid (Gene therapy)NCT00566657SanofiCritical limb ischemiaCompleted (failure to detect efficacy)Cerepro (cancer vaccine)EUDRACT2004-000464--28.Ark TherapeuticsOperable high-grade gliomaCompleted; MAA withdrawn (unable to demonstrate a clinically meaningful benefit)Autologous chondrocytesEUDRACT2016-002817--22TETEC Tissue Engineering Technologies -- AGCartilage damageActiveKeratinocytesEUDRACT2012-003286--18Smith & NephewChronic leg ulcerTerminated (failure to detect efficacy)Autologous dendritic cellsEUDRACT2012-000871--17Argos Therapeutics, Inc.Renal cell carcinoma stage IVActiveAutologous dendritic cellsNCT02111577Sotio a.s.Metastatic castration resistant prostate cancerActiveCancer vaccineNCT01383148TransgeneNon small cell lung cancerTerminated (reason unclear)Pexa-Vec (Cancer vaccine)NCT02562755SillaJen, Inc.Hepatocellular CarcinomaRecruitingAVXS-101 (Gene Therapy)NCT03461289AveXis, Inc.Spinal Muscle AtrophyRecruitingCER-001 (Gene Therapy)NCT02697136Cerenis Therapeutics, SAPrimary HypoalphalipoproteinemiaRecruitingAutologous fat enhanced with regenerative cellsNCT00616135Cytori TherapeuticsCosmetic breast deformitiesCompletedAMG0001 (Gene Therapy)NCT02144610AnGes USA, Inc.Critical limb ischemiaTerminated (strategy amendment)Autologous Muscle Derived CellsNCT01893138Cook MyoSite\|Cook Group IncorporatedFemale Urinary Sphincter RepairActive, not recruitingCancer vaccineNCT01817738CureVac AGProstate cancerTerminatedValoctocogene Roxaparvovec (Gene Therapy)NCT03392974BioMarin PharmaceuticalHemophilia ARecruitingAAVrh10-h.SGSH Gene TherapyNCT03612869LYSOGENEMucopoly-saccharidosisNot yet recruitingBone marrow stem cellsNCT00462774Miltenyi Biotec GmbHIschaemic heart failureCompletedProgenitor CellsNCT00279175Eli Lilly and CompanyAcute Myocardial InfarctionCompletedCancer vaccineNCT00676507NovaRx CorporationNon-small Cell Lung CancerCompletedGSK2696274 (Gene Therapy)NCT03392987GlaxoSmithKlineMetachromatic LeukodystrophyRecruitingMesenchymal Stem CellsNCT00366145Osiris TherapeuticsAcute Graft Versus Host DiseaseCompletedNiCord® cord blood stem cellsNCT02730299Gamida Cell ltdHematologic malignanciesRecruitingTG4010 (Cancer vaccine)NCT00415818TransgeneNon-Small Cell Lung CancerCompletedDCVax®-L (Cancer vaccine)NCT00045968Northwest BiotherapeuticsGlioblastomaUnknown statusAAV2-REP1(Gene Therapy)NCT03496012Nightstar TherapeuticsChoroideremiaRecruiting10.1080/20016689.2019.1600939-F0003Figure 3.Potential ATMP candidates in industry-driven phase III clinical trials.

The majority of clinical trials performed in an academic setting target stem cell transplantation for oncological indications (68%). Most of them are not embraced by the ATMP definition, as autologous stem cells for transplantation after chemotherapy are usually neither substantially manipulated nor intended to be used for a different essential function. Other indications are myocardial infarction and heart failure (9%), critical limb ischemia (6%), stroke, burns and infertility. Except for one tumor vaccine, all academic clinical trials investigate cell therapeutic products ([Figure 4](#F0004)). Details on ATMP candidates developed in academic settings are presented in [Table 7](#T0007).10.1080/20016689.2019.1600939-T0007Table 7.Overview on academic phase III/IV ATMP clinical trials (Stem cell transplantation for haematological malignancies not included).Trial IdentifierPhaseSponsorProduct/ProcedureIndicationNCT00434616IIIFranziskus-KrankenhausAutologous bone marrow cellsCritical limb ischemiaNCT01803347IIIInstituto de Investigación Sanitaria de la Fundación Jiménez DíazAutologous expanded adipose-derived stem cellsAnal fistulaNCT01569178IIIQueen Mary University of LondonBone marrow derived mononuclear cellsAcute myocardia infarctionNCT03477500IIINCT03477500 Haukeland University HospitalAutologous stem cellsMultiple sclerosisISRCTN54371254IIIEBMT Central OfficeAutologous hematopoietic stem cellsDiffuse cutaneous systemic sclerosisEUDRACT2015-000431--32IIIUniversidad Autónoma de Madrid (U.A.M.)Autologous human bone marrow-derived expanded mesenchymal stromal cellsDiaphyseal metaphyseal fracture and non unionn/aIIIUnknownRenal cell tumor vaccineRenal carcinomaNCT00297193IIIEuropean Group for Blood and Marrow Transplantation \| The Broad FoundationAutologous Stem CellsCohn's DiseaseNCT02437708IIIUniversitaire Ziekenhuizen LeuvenStem cellsPeriapical bone healing in infected immature primary teethNCT01818310II\|IIIUniversity Hospital Ostrava\|Ministry of Health, Czech Republic\|Regional Council of the Moravian-Silesian region, KU MSKAutologous Bone Marrow Aspirate ConcentrateNo-Option Critical Limb IschemiaNCT02849613II\|IIIUniversity Hospital, GrenobleRegenerative Stem Cell TherapyStrokeNCT00904501IIICHU de Reims \|Etablissement Francais du SangBone Marrow AutograftLimb IschemiaNCT03325504IIIUniversidad Autonoma de MadridMesenchymal stem cells + BiomaterialBone Healing in Non-UnionNCT01489501IIICellSeed France S.A.R.L.\|FGK Clinical Research GmbHOral mucosal epithelial cell sheetLimbal Stem Cell DeficiencyNCT00938847IIIAsklepios proresearch Cordis CorporationBone Marrow Derived MononuclearMyocardial RegenerationNCT01983748IIIUniversity Hospital ErlangenDendritic Cells Plus Autologous Tumor RNAUveal MelanomaNCT01693042II\|IIIJohann Wolfgang Goethe University HospitalAutologous Bone Marrow-derived Mononuclear CellsChronic Post-infarction Heart FailureNCT01753440II\|IIIAHEPA University HospitalAllogeneic Stem Cells Implantation Combined With Coronary Bypass GraftingIschemic CardiomyopathyNCT01759212II\|IIIAHEPA University HospitalLeft Ventricular Assist Device + Allogeneic Mesenchymal Stem Cells ImplantationEnd-stage Heart FailureNCT03112122IVIstituto Ortopedico RizzoliBone Marrow ConcentrateBone Marrow EdemaNCT03110679IVIstituto Ortopedico RizzoliAutologous Bone Marrow ConcentrateOsteoarthritisNCT02454231II\|IIIUniversity of Florence\|Tuscany RegionStem CellsLife Threatening Limbs ArteriopathyNCT00539266II\|IIILeiden University Medical CentreAutologous Bone Marrow-derived Mononuclear CellsLimb IschemiaNCT03042572II\|IIIThe Netherlands Organisation for Health Research and Development\|UMC UtrechtAllogeneic Mesenchymal Stromal CellsNo-option Ischemic LimbsNCT01343836II\|IIIErasmus Medical CenterAutologous Tenocyte ImplantationChronic Achilles TendinopathyNCT03229564II\|IIIUniversity of Zurich\|ETH Zurich (Switzerland)\|Julius Clinical, The NetherlandsAutologous Dermo-epidermal Skin SubstituteTreatment of Burns in ChildrenNCT02323620IIIAmerican Heart of PolandBone marrow derived mononuclear cellsMyocardial infarctionNCT03404063II\|IIIJohn Paul II Hospital, Krakow\|KCRI\|National Center for Research and Development, PolandCardioCell (Wharton´s Jelly derived mesenchymal stem cells)Acute Myocardial InfarctionNCT03423732II\|IIIJohn Paul II Hospital, Krakow\|KCRI\|National Center for Research and Development, PolandCardioCell (Wharton´s Jelly derived mesenchymal stem cells)No-option Critical Limb IschemiaNCT02248532II\|IIIUniversity Medical Centre LjubljanaCD34+ CellsDilated CardiomyopathyNCT02144987IVInstituto Valenciano de Infertilidad, IVI VALENCIABone Marrow Stem CellsAsherman's Syndrome and Endometrial AtrophyNCT03535480IVInstituto de Investigacion Sanitaria La FeAutologous Bone Marrow Stem CellsPremature Ovarian FailureNCT02389010IIICentro Nazionale Sangue\|Italian National Cord Blood NetworkPlatelet Gel From Cord BloodDiabetic Foot UlcersNCT00747708II\|IIIBarts & The London NHS TrustBone Marrow Derived Adult StemChronic Heart Failure10.1080/20016689.2019.1600939-F0004Figure 4.Stem cell therapies and potential ATMP candidates applied in academic phase III and IV clinical trials.

Conclusion {#S0004}
==========

Advanced therapeutic medicinal therapies are still in their early days, but constantly evolving. Until 2017, more than 900 ATMPs have been examined in clinical trials worldwide \[[39](#CIT0039)\]. Despite this impressive number of projects, the number of ATMPs on the market is still considerably low, and some of them were withdrawn only a couple of years after their market launch. Up to date, there are 8 ATMPs available via a centralized European marketing authorisation. Information on their commercial success is still very limited. GlaxoSmithKline, for example, has announced the first reimbursement of Strimvelis**®** for its first patient in March 2017 despite being approved under a full performance-based reimbursement scheme since 2016 \[[40](#CIT0040)\].

7 European Union member states reported providing additional ATMPs outside of clinical trials via Hospital exemption regulation. Due to a poor return rate, the data of the 2018 survey are of limited significance. However, combining the actual data with the results of the 1012 report published by the European Commission \[[37](#CIT0037)\], there are still only 8 countries having issued Hospital exemptions. At the 26th Annual EuroMeeting in Vienna, concerns were raised that European member states might consider the Hospital exemption as an opportunity for early clinical development prior to clinical trials \[[41](#CIT0041)\]. ATMPs that had been legally on the market before 2008 might avoid the complex authorisation procedure by evading under the Hospital exemption regulation. However, considering the actual survey result in combination with the 2012 data, these concerns have not been verified on a large scale.

6 new ATMPs shall be launched until 2020 and offer new treatment modalities for retinal dystrophy, ß-thalassemia, scleroderma, sickle-cell anaemia, adrenoleukodystrophy and leukaemia. **Luxturna™, LentiGlobin™** and **ATIR101** have already submitted a central marketing authorization application. For Luxturna™, the Committee for Medicinal products for Human Use has issued a positive opinion recommending approval \[[42](#CIT0042)\]. **LentiGlobin™** has been granted accelerated assessment by the EMA and ATIR101 expects conditional approval in 2019 \[[43](#CIT0043),[44](#CIT0044)\]. **Habeo**™ and **Neocart**® did not reach significance in the primary efficacy endpoints in their respective phase III clinical trials, and eventual consequences for their marketing launch are unclear. For **LentiD™**, a modified paediatric investigation plan was accepted by the EMA in September 2018 \[[45](#CIT0045)\]. 7 additional ATMPs currently in phase III clinical development are planned for a marketing authorisation application in or after 2020.

131 phase III clinical trials with ATMPs could be identified apart from the centralized marketing authorisation procedure. 31 ATMP candidates are industrial research projects with an assumptive interest in obtaining a marketing authorisation. However, reaching phase III stage does not guarantee a roadmap to successful clinical translation: Out of 19 finalized clinical trials, 26% were terminated prematurely and 23% of the ATMP candidates finally failed to demonstrate efficacy when evaluated against the current standard of care.
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[^1]: ALL ... Acute Lymphoblastic Leukaemia

    DLBCL ... Diffuse Large B Cell Lymphoma

    ADA-SCID ... Adenosine Deaminase Severe Combined Immunodeficiency

[^2]: EMA ... European Medicines Agency

    MAA ... Marketing Authorisation Application

    CHMP ... Committee for Medicinal products for Human Use

    AML ... Acute Myeloid Leukaemia

    ALL ... Acute Lymphoblastic Leukaemia

    DLBCL ... Diffuse Large B Cell Lymphoma

    EBV .... Epstein Barr Virus

    PRIME ...PRIority MEdicines scheme
